Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.

BACKGROUND Viruses resistant to zanamivir have been generated in vitro, but no resistant virus has yet been isolated from a zanamivir-treated immunocompetent patient. In contrast most resistant viruses isolated from oseltamivir-treated patients correspond to those selected in vitro. However, despite mutations being in conserved residues in the neuraminidase (NA) they do not confer resistance in all NA subtypes. OBJECTIVES AND METHODS We have used reverse genetics and the recombinant baculovirus expression system for investigating reasons for the lack of isolation of zanamivir-resistant H3N2 viruses and for further exploring subtype-specific oseltamivir resistance. RESULTS H3N2 viruses generated by reverse genetics with H274Y, R292K E119V and E119D mutations were rescued. Those with E119G, E119A or R152K mutations could only be rescued in the presence of exogenous NA and after passage in the absence of exogenous NA only isolates that had reverted to the wild-type NA or, surprisingly, E119G/A to E119V NA were isolated. Mutations conferring zanamivir resistance significantly affected enzyme activity, virus replication or NA thermal stability. E119V viruses were stable and grew to similar titres as wild-type virus, consistent with their isolation from oseltamivir-treated patients. Mutations conferring oseltamivir resistance in N1 (H274Y) and B (R152K) NAs also conferred resistance in recombinant G70C N9 NA expressed in insect cells. CONCLUSIONS These data suggest that zanamivir-resistant H3N2 viruses may not readily arise in vivo due to their poor viability. The G70C N9 NA may also provide a useful model for understanding the structural basis of subtype-specific drug resistance.

[1]  F. Hayden,et al.  Evaluation of Neuraminidase Enzyme Assays Using Different Substrates To Measure Susceptibility of Influenza Virus Clinical Isolates to Neuraminidase Inhibitors: Report of the Neuraminidase Inhibitor Susceptibility Network , 2003, Journal of Clinical Microbiology.

[2]  P. Ward,et al.  Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. , 2005, The Journal of antimicrobial chemotherapy.

[3]  R. Webster,et al.  Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. , 1998, The Journal of infectious diseases.

[4]  P. Colman,et al.  Mutations in a Conserved Residue in the Influenza Virus Neuraminidase Active Site Decreases Sensitivity to Neu5Ac2en-Derived Inhibitors , 1998, Journal of Virology.

[5]  A. van Donkelaar,et al.  Structural evidence for a second sialic acid binding site in avian influenza virus neuraminidases. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[6]  D. Mendel,et al.  Mechanism by Which Mutations at His274 Alter Sensitivity of Influenza A Virus N1 Neuraminidase to Oseltamivir Carboxylate and Zanamivir , 2002, Antimicrobial Agents and Chemotherapy.

[7]  P. Colman,et al.  Three‐dimensional structure of the complex of 4‐guanidino‐Neu5Ac2en and influenza virus neuraminidase , 1995, Protein science : a publication of the Protein Society.

[8]  Paul W Smith,et al.  Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. , 1998, Structure.

[9]  V. Stoll,et al.  In Vitro Selection and Characterization of Influenza A (A/N9) Virus Variants Resistant to a Novel Neuraminidase Inhibitor, A-315675 , 2002, Journal of Virology.

[10]  Brian J Smith,et al.  Structural studies of the resistance of influenza virus neuramindase to inhibitors. , 2002, Journal of medicinal chemistry.

[11]  G. Boivin,et al.  A Reverse Genetics Study of Resistance to Neuraminidase Inhibitors in An Influenza A/H1N1 Virus , 2003, Antiviral therapy.

[12]  R. Webster,et al.  Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en , 1996, Journal of virology.

[13]  A. Kortt,et al.  A new method for the purification of the influenza A virus neuraminidase. , 1991, Journal of virological methods.

[14]  W G Laver,et al.  Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. , 1997, Journal of the American Chemical Society.

[15]  A J Elliott,et al.  BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. , 2000, Journal of medicinal chemistry.

[16]  P. Colman,et al.  Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme. , 1996, Virology.

[17]  J. McKimm-Breschkin.  Management of Influenza Virus Infections with Neuraminidase Inhibitors , 2012, Treatments in respiratory medicine.

[18]  P. Colman,et al.  Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. , 1995, Virology.

[19]  J. McKimm-Breschkin,et al.  Resistance of influenza viruses to neuraminidase inhibitors--a review. , 2000, Antiviral research.

[20]  S. de la Luna,et al.  Synthesis of biologically active influenza virus core proteins using a vaccinia virus-T7 RNA polymerase expression system. , 1994, The Journal of general virology.

[21]  R. Bethell,et al.  In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. , 1999, Virology.

[22]  G. Air,et al.  Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. , 1995, Virology.

[23]  I. Barr,et al.  In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors. , 2004, Antiviral research.

[24]  G. Air,et al.  Three‐dimensional structure of neuraminidase of subtype N9 from an avian influenza virus , 1987, Proteins.

[25]  M Tisdale,et al.  Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors , 2000, Reviews in medical virology.

[26]  A. van Donkelaar,et al.  Refined atomic structures of N9 subtype influenza virus neuraminidase and escape mutants. , 1992, Journal of molecular biology.

[27]  G. Air,et al.  Antigenic structure and variation in an influenza virus N9 neuraminidase , 1987, Journal of virology.

[28]  Yoshihiro Kawaoka,et al.  oseltamivir: descriptive study , 2022 .

[29]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[30]  R. Webster,et al.  Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en , 1997, Journal of virology.

[31]  W. Barclay,et al.  Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. , 2005, The Journal of antimicrobial chemotherapy.

[32]  H. Goto,et al.  Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. , 1997, Virology.

[33]  W. Barclay,et al.  A Reverse Genetics Approach for Recovery of Recombinant Influenza B Viruses Entirely from cDNA , 2002, Journal of Virology.

[34]  R. Bethell,et al.  Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. , 2000, Analytical biochemistry.

[35]  R. Tjian,et al.  Analysis of clustered point mutations in the human ribosomal RNA gene promoter by transient expression in vivo. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[36]  P. Colman,et al.  The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor , 1992, Proteins.

[37]  Hideo Goto,et al.  Avian flu: Isolation of drug-resistant H5N1 virus , 2005, Nature.

[38]  F. Hayden,et al.  Neuraminidase Sequence Analysis and Susceptibilities of Influenza Virus Clinical Isolates to Zanamivir and Oseltamivir , 2003, Antimicrobial Agents and Chemotherapy.

[39]  A. Beloso,et al.  Influenza virus NS1 protein inhibits pre‐mRNA splicing and blocks mRNA nucleocytoplasmic transport. , 1994, The EMBO journal.